2023
Onconephrology: Core Curriculum 2023
Yarandi N, Shirali A. Onconephrology: Core Curriculum 2023. American Journal Of Kidney Diseases 2023, 82: 743-761. PMID: 37855786, DOI: 10.1053/j.ajkd.2023.04.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseChimeric antigen receptor T cellsAntigen receptor T cellsAJKD's Core CurriculumAcute kidney injuryKidney transplant recipientsChronic kidney diseaseReceptor T cellsKidney injuryTransplant recipientsElectrolyte disordersCell transplantClinical syndromeMonoclonal gammopathyGlomerular diseaseT cellsCancer riskClinical decisionCancer treatmentDiseaseOnconephrologySyndromeCancerSpecific considerationsHypertensionOnco-Nephrology Kidney Disease in the Cancer Patient
Yarandi N, Shirali A. Onco-Nephrology Kidney Disease in the Cancer Patient. Medical Clinics Of North America 2023, 107: 749-762. PMID: 37258012, DOI: 10.1016/j.mcna.2023.03.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseAcute kidney injuryChronic kidney diseaseDifferent clinical manifestationsSubspecialty of nephrologyOnco-NephrologyKidney injuryElectrolyte disturbancesClinical manifestationsCancer patientsGeneral internistsPatientsDiseaseCancerHypertensionProteinuriaInternistsInjuryNephrology
2022
Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY
Shirali AC. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY. Kidney360 2022, 3: 806-808. PMID: 36129422, PMCID: PMC9438420, DOI: 10.34067/kid.0005592021.Commentaries, Editorials and LettersMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryCreatinineHumansImmune Checkpoint InhibitorsKidneyNephritis, InterstitialConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2020
Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study
Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study. Journal Of The American Society Of Nephrology 2020, 31: 435-446. PMID: 31896554, PMCID: PMC7003302, DOI: 10.1681/asn.2019070676.Peer-Reviewed Original ResearchConceptsExtrarenal immune-related adverse eventsImmune-related adverse eventsMulticenter studyRenal prognosisKidney recoveryAdverse eventsMost patientsClinical featuresCombination immune checkpoint inhibitor therapyImmune checkpoint inhibitor initiationImmune checkpoint inhibitor rechallengeImmune checkpoint inhibitor therapyProton pump inhibitor useComplication of immunotherapyLower baseline eGFRNew dialysis requirementWorse renal prognosisCheckpoint inhibitor therapyImmune checkpoint inhibitorsCheckpoint inhibitor initiationBaseline eGFRSubnephrotic proteinuriaCheckpoint inhibitorsDialysis requirementControl patients